No adverse reactions considered as drug-related were reported in patients treated with sitagliptin occurring in excess (> 0.2% and difference > 1 patient) of that in patients treated with control.
Sitagliptiiniga ravitud patsientidel ei esinenud ravimiga seotud kõrvaltoimeid sagedamini (> 0, 2% ja erinevus > 1 patsient) kui kontrollravimit saanud patsientidel.